Detalles de la búsqueda
1.
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Mult Scler
; 30(4-5): 558-570, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38436271
2.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
N Engl J Med
; 383(6): 546-557, 2020 08 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32757523
3.
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
J Neurol Neurosurg Psychiatry
; 94(1): 1-9, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36418156
4.
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
Mult Scler
; 29(11-12): 1471-1481, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37626477
5.
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Mult Scler
; 27(14): 2219-2231, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33769117
6.
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Mult Scler
; 27(10): 1564-1576, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33205682
7.
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.
Eur J Neurol
; 28(12): 4135-4145, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431170
8.
Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
Mult Scler
; 26(13): 1670-1681, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31610732
9.
Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials.
Mult Scler
; 26(8): 993-996, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31060429
10.
A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
J Med Internet Res
; 22(2): e16932, 2020 02 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32049062
11.
Learning ability correlates with brain atrophy and disability progression in RRMS.
J Neurol Neurosurg Psychiatry
; 90(1): 38-43, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30322898
12.
Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset.
Brain Topogr
; 31(5): 886-894, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29845492
13.
"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
Mult Scler
; 23(9): 1179-1187, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28381105
14.
Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
Mult Scler
; 23(5): 656-664, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27411701
15.
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
J Neurol Neurosurg Psychiatry
; 87(5): 468-75, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26111826
16.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Mult Scler
; 22(10): 1297-305, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26585439
17.
Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
Neurology
; 102(5): e208058, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38335474
18.
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.
Neurodegener Dis Manag
; 13(4): 207-213, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37345645
19.
Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Neurology
; 98(21): e2120-e2131, 2022 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35379762
20.
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study.
Brain Sci
; 12(2)2022 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35203978